You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,491,882


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,491,882
Title:Methods for reducing the risk of an unsuccessful pregnancy in a subject having an immune system abberation
Abstract: Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).
Inventor(s): Carter; Darryl L. (Owings Mills, MD)
Assignee: Nora Therapeutics, Inc. (Palo Alto, CA)
Application Number:13/342,512
Patent Claims:1. A method for reducing the risk of an unsuccessful pregnancy in a human female identified as having elevated Th1 cell number, elevated Th1 cell activity, elevated amount of a Th1 cell product, decreased Th2 cell number, decreased Th2 cell activity, decreased amount of a Th2 cell product, a higher ratio of Th1 cell number to Th2 cell number, or a higher ratio of Th1 cell activity to Th2 cell activity, individually as compared to prior to pregnancy or a healthy pregnancy, comprising administering to the human female having an immune system aberration a dose of a granulocyte colony stimulating factor (G-CSF) ranging from 1 to 100 mcg (micrograms)/kg/day and wherein the female is at risk of an unsuccessful pregnancy.

2. The method of claim 1 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 20 mcg/kg/day.

3. The method of claim 1 wherein the G-CSF is administered at a dose ranging from 1 mcg/kg/day to 10 mcg/kg/day.

4. The method of claim 1 wherein the G-CSF is filgrastim or pegfilgrastim.

5. The method of claim 1 wherein the G-CSF is administered to a human female having an elevated Th1 cell number, elevated Th1 cell activity, elevated amount of a Th1 cell product.

6. The method of claim 1 wherein the G-CSF is administered to a human female having a higher ratio of Th1 cell number to Th2 cell number, a higher ratio of Th1 cell activity to Th2 cell activity, or both.

7. The method of claim 1 wherein the G-CSF is administered until the human female recipient has a normal Th1 response, a normal Th2 response, or both.

8. The method of claim 1 wherein the Th1 cell product is interferon .gamma..

9. The method of claim 1 wherein the Th1 cell product is tumor necrosis factor .beta..

10. The method of claim 1 wherein the Th1 cell product is IL-2.

11. The method of claim 1 wherein the Th2 cell product is IL-4, IL-5, IL-6, IL-10, IL-3, or any combination thereof.

12. The method of claim 1 wherein the Th2 cell product is IL-10.

13. The method of claim 1 wherein the Th1 cell product is interferon .gamma., tumor necrosis factor .beta. or both, and the Th2 cell product is IL-10.

14. The method of claim 1 wherein the human female previously had one or more spontaneous abortions, two or more spontaneous abortions, or recurrent spontaneous abortions.

15. The method of claim 1 wherein the human female recipient is in the first trimester of pregnancy, or is in the first or second month of pregnancy.

16. The method of claim 1 wherein the G-CSF is administered daily.

17. The method of claim 1 wherein the G-CSF is administered daily for one week.

18. The method of claim 1 wherein the G-CSF is administered daily for two weeks.

19. The method of claim 1 wherein the G-CSF is administered daily for four, three, two or one week during the first trimester of pregnancy.

20. The method of claim 1 wherein the G-CSF is administered for at least five consecutive days during the first or second trimester of pregnancy, or for at least five consecutive days during the first or second week of pregnancy.

21. The method of claim 1 wherein the G-CSF is administered through the end of pregnancy.

22. The method of claim 1 wherein the G-CSF is administered for the duration of pregnancy.

23. The method of claim 1 wherein the G-CSF is administered daily for one to thirty-five consecutive days.

24. The method of claim 1 wherein the G-CSF is administered in the first 20 weeks of pregnancy.

25. The method of claim 24 wherein the G-CSF is administered for one day, two days, three days, four days, or five days.

26. The method of claim 1 wherein the G-CSF is administered in the first or second month of pregnancy.

27. The method of claim 1 wherein the G-CSF is administered daily until the end of the first trimester.

28. The method of claim 1 wherein the G-CSF is administered during the first or second trimester of pregnancy.

29. The method of claim 1 wherein the G-CSF is administered in the second trimester of pregnancy, third trimester of pregnancy, or both.

30. The method of claim 1 wherein the G-CSF is administered for four, three, two or one week.

31. The method of claim 1 wherein the G-CSF is administered for five, four, three, or two days.

32. The method of claim 1 wherein the G-CSF is administered parenterally, enterally, subcutaneously, percutaneously, transdermally, intradermally, intravenously, topically, by inhalation, or by implantation.

33. The method of claim 1 wherein the G-CSF is administered with another active agent.

34. The method of claim 33 wherein the other active agent is an immunosuppressive agent.

35. The method of claim 1 wherein the G-CSF is formulated as a composition comprising a pharmaceutically acceptable carrier or diluent.

36. The method of claim 1 wherein the G-CSF is formulated for prolonged delivery.

37. The method of claim 36 wherein the prolonged delivery results from a formulation comprising G-CSF conjugated to a water soluble polymer.

38. The method of claim 37 wherein the G-CSF conjugated to a water soluble polymer is pegfilgrastim.

39. The method of claim 36 wherein the G-CSF is formulated for prolonged delivery with a polymeric or a hydrophobic material.

40. The method of claim 36 wherein the prolonged delivery formulation comprises an inert matrix or device.

41. The method of claim 36 wherein the prolonged delivery formulation comprises an adhesive disc or patch capable of slowly releasing G-CSF for percutaneous, transdermal, or intradermal adsorption.

42. The method of claim 41 wherein the disc or patch further comprise a skin permeation enhancer.

43. The method of claim 1 wherein the human female was a recipient of an assisted reproduction procedure.

44. The method of claim 43 wherein the assisted reproduction procedure is in vitro fertilization, artificial insemination, or gamete intrafallopian tube transfer.

45. The method of claim 1 wherein the G-CSF is administered subcutaneously.

Details for Patent 8,491,882

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 02/20/1991 ⤷  Try a Trial 2023-10-24
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 06/28/2000 ⤷  Try a Trial 2023-10-24
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 01/31/2002 ⤷  Try a Trial 2023-10-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.